BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 11160278)

  • 1. Diverse repertoire of the MHC class II-peptide complexes is required for presentation of viral superantigens.
    Golovkina T; Agafonova Y; Kazansky D; Chervonsky A
    J Immunol; 2001 Feb; 166(4):2244-50. PubMed ID: 11160278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MHC class II hierarchy of superantigen presentation predicts efficiency of infection with mouse mammary tumor virus.
    Held W; Waanders GA; MacDonald HR; Acha-Orbea H
    Int Immunol; 1994 Sep; 6(9):1403-7. PubMed ID: 7819149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B and T cells are required for mouse mammary tumor virus spread within the mammary gland.
    Golovkina TV; Dudley JP; Ross SR
    J Immunol; 1998 Sep; 161(5):2375-82. PubMed ID: 9725233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial stages of mammary tumor virus infection are superantigen independent.
    Pobezinskaya Y; Chervonsky AV; Golovkina TV
    J Immunol; 2004 May; 172(9):5582-7. PubMed ID: 15100301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of MHC class II-associated peptides that promote the presentation of toxic shock syndrome toxin-1 to T cells.
    Hogan RJ; VanBeek J; Broussard DR; Surman SL; Woodland DL
    J Immunol; 2001 Jun; 166(11):6514-22. PubMed ID: 11359802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. H2-O inhibits presentation of bacterial superantigens, but not endogenous self antigens.
    Qi L; Ostrand-Rosenberg S
    J Immunol; 2001 Aug; 167(3):1371-8. PubMed ID: 11466355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell receptor-major histocompatibility complex class II interaction is required for the T cell response to bacterial superantigens.
    Labrecque N; Thibodeau J; Mourad W; Sékaly RP
    J Exp Med; 1994 Nov; 180(5):1921-9. PubMed ID: 7964467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of CD28 costimulation in immune-mediated responses against mouse mammary tumor viruses.
    Palmer LD; Saha B; Hodes RJ; Abe R
    J Immunol; 1996 Mar; 156(6):2112-8. PubMed ID: 8690899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A V beta 4-specific superantigen encoded by a new exogenous mouse mammary tumor virus.
    Maillard I; Erny K; Acha-Orbea H; Diggelmann H
    Eur J Immunol; 1996 May; 26(5):1000-6. PubMed ID: 8647159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD28/CTLA4-B7 interaction is dispensable for T cell stimulation by mouse mammary tumor virus superantigen but not for B cell differentiation and virus dissemination.
    Champagne E; Scarpellino L; Lane P; Acha-Orbea H
    Eur J Immunol; 1996 Jul; 26(7):1595-602. PubMed ID: 8766566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of dendritic cells in the immune response induced by mouse mammary tumor virus superantigen.
    Baribaud F; Maillard I; Vacheron S; Brocker T; Diggelmann H; Acha-Orbea H
    J Virol; 1999 Oct; 73(10):8403-10. PubMed ID: 10482591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A highly sensitive in vitro infection assay to explore early stages of mouse mammary tumor virus infection.
    Vacheron S; Renno T; Acha-Orbea H
    J Virol; 1997 Oct; 71(10):7289-94. PubMed ID: 9311804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of MMTV superantigen presentation in MHC class II-deficient mice.
    Beutner U; McLellan B; Kraus E; Huber BT
    Cell Immunol; 1996 Mar; 168(2):141-7. PubMed ID: 8640859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concomitant infection with exogenous mouse mammary tumor virus encoding I-E-dependent superantigen in I-E-negative mouse strain.
    Ando Y; Wajjwalku W; Niimi N; Hiromatsu K; Morishima T; Yoshikai Y
    J Immunol; 1995 Jun; 154(12):6219-26. PubMed ID: 7759859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superantigens of mouse mammary tumor virus.
    Acha-Orbea H; MacDonald HR
    Annu Rev Immunol; 1995; 13():459-86. PubMed ID: 7612231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational and functional analysis of the C-terminal region of the C3H mouse mammary tumor virus superantigen.
    Wrona TJ; Lozano M; Binhazim AA; Dudley JP
    J Virol; 1998 Jun; 72(6):4746-55. PubMed ID: 9573239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BALB/Mtv-null mice responding to strong mouse mammary tumor virus superantigens restrict mammary tumorigenesis.
    Bhadra S; Lozano MM; Dudley JP
    J Virol; 2009 Jan; 83(1):484-8. PubMed ID: 18922863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Requirement of class II and membrane proximal region of mouse mammary tumor virus superantigen (Mtv SAG) in Mtv7 SAG presentation].
    Okamoto M; Kimura S; Katagiri M
    Hokkaido Igaku Zasshi; 1998 May; 73(3):205-14. PubMed ID: 9719947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of the rat T cell response to retroviral and bacterial superantigens by class II MHC products and Tcrb-V8.2 alleles.
    Herrmann T; Hochgrebe T; Torres-Nagel NE; Huber BT; Hünig T
    J Immunol; 1994 May; 152(9):4300-9. PubMed ID: 8157953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo effects of a recombinant vaccinia virus expressing a mouse mammary tumor virus superantigen.
    Krummenacher C; Diggelmann H; Acha-Orbea H
    J Virol; 1996 May; 70(5):3026-31. PubMed ID: 8627779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.